Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer - Wikidata - thesis-toulmin - TriplyDB

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

http://www.wikidata.org/entity/Q28305293

about

KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Current targeted therapies in the treatment of advanced colorectal cancer: a review Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Molecular testing to optimize therapeutic decision making in advanced colorectal cancer Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis Treatment of colorectal cancer in the elderly Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention Molecular phenotypes of colorectal cancer and potential clinical applications Correlation of human epidermal growth factor receptor protein expression and colorectal cancer Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups Personalized treatment for advanced colorectal cancer: KRAS and beyond Management of colorectal cancer Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Role of surgery in colorectal cancer liver metastases Recent applications of chemosensitivity tests for colorectal cancer treatment Molecular alterations and biomarkers in colorectal cancer The next steps in next-gen sequencing of cancer genomes KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.Role of targeted therapy in metastatic colorectal cancer Multisciplinary management of patients with liver metastasis from colorectal cancer Tumour biomarkers: homeostasis as a novel prognostic indicator RAS and BRAF in metastatic colorectal cancer management Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers Standard chemotherapy with cetuximab for treatment of colorectal cancer Catumaxomab: clinical development and future directions A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy

P2860

Q21128654-532B9E5E-D17C-40ED-B9E4-FBACBB2505DD Q21142734-8C103C95-DBE9-49F0-A88F-08E81E8BAE90 Q24600031-E9720C6E-28E5-41A3-B13E-1C1F817410B3 Q26740067-A5AD1EEF-A9A2-4FE9-A658-77B28DF2EA4A Q26747335-E9DC20AA-1830-4099-9F8F-ADD4125EED44 Q26748924-746E9C3C-516F-438D-ACA5-46813D8BCD7D Q26749012-364EE2FF-0EEE-4D9A-B2EF-38527A60FF31 Q26752747-00281926-F8A0-4140-9E03-F33D611B7E3F Q26766535-EC62E675-59A3-416F-BDE2-DD600D1FF072 Q26769884-3852A17D-284A-4C9B-BD64-2CA290ED7208 Q26769958-86B8896A-F65C-4A0C-8CDE-59F46996D958 Q26774605-FD57DDB8-3BAE-47FE-8918-28A7BADA1EC5 Q26774704-8CD35136-993F-400E-974D-B77DF0FA09BA Q26777704-DA585494-C852-4F13-9E99-44F30E71DC94 Q26781457-0E436A26-B5DF-48BB-A169-C6F5BB5ADA08 Q26782809-B5BC37A0-1BD1-46E3-B57B-83B7C2CB5AAB Q26785725-0E748789-F3C7-44EF-BDB1-F5A6C8CAEB8B Q26801167-98803380-3046-4EA4-ADD4-BD0CC27A7211 Q26822395-FC4BBDAD-2607-488D-81AC-78B9C286B40B Q26822817-9D7A6E29-26DE-4E2B-8199-7615392F9FE5 Q26823550-17B8007B-0B6A-456E-8B08-5E935BE0C094 Q26826817-F40198D4-7995-4CD7-A506-16A0DD57FD17 Q26828992-ABB68426-E6E9-4BBB-8A2D-AE317D1F5FE1 Q26830444-CF910BAC-E347-4A31-BD0D-53CEC9D15122 Q26851075-93266307-1D91-4DF5-890C-55CF70C3B823 Q26862317-6C93F65C-F5BC-4F01-B615-642EB1FF9959 Q26998894-07BF2034-D57C-4C2F-BBD9-77E2E5B16792 Q27851532-AFE95F2B-3C2A-437E-ADD3-E9AD7D4D3724 Q27851592-C20EFD80-78D4-42C6-A918-1D4639F27C3F Q27851674-4CD5A3EF-8BB9-469D-9DFA-7F19F2686EEF Q27851708-4236721B-07E8-4AAA-810D-C34E2890FA91 Q28068817-7ECFBF94-C3B8-45C0-8861-6A0F95B4DF1F Q28069575-2B0A94E3-166A-4D38-BC33-8984D5361CAC Q28069898-DDF5AB44-065E-41BC-9A05-AE898A5321DE Q28074175-871FB877-EBAA-4996-A17C-560978036BF4 Q28084216-55D74805-4418-467E-8491-1F8264BDF3B4 Q28087333-1296490C-6BC7-4FEC-B872-313034F4D0EF Q28088693-F5176573-0A35-47E8-B490-194E4774949A Q28274519-1DEA584C-46BC-46B4-A35B-44DAC589C272 Q28287088-CA925690-D9B1-45C5-8889-4C0002A5FCFB

P2860

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

http://www.wikidata.org/entity/Q28305293

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Fluorouracil, leucovorin, and ...... f metastatic colorectal cancer

@ast

Fluorouracil, leucovorin, and ...... f metastatic colorectal cancer

@en

Fluorouracil, leucovorin, and ...... f metastatic colorectal cancer

@nl

type

label

Fluorouracil, leucovorin, and ...... f metastatic colorectal cancer

@ast

Fluorouracil, leucovorin, and ...... f metastatic colorectal cancer

@en

Fluorouracil, leucovorin, and ...... f metastatic colorectal cancer

@nl

prefLabel

Fluorouracil, leucovorin, and ...... f metastatic colorectal cancer

@ast

Fluorouracil, leucovorin, and ...... f metastatic colorectal cancer

@en

Fluorouracil, leucovorin, and ...... f metastatic colorectal cancer

@nl

P1433

Q28305293-BDE1280B-64CD-4536-B28B-CF36522AB934

P1476

Q28305293-690573CD-FF4C-4475-B470-C88BE5AB3C5C

P2093

Q28305293-05386A17-FFA7-4A46-A88F-CF78B3454873

Q28305293-0D1BFEC0-7C9E-487D-9309-F33F268AC56A

Q28305293-267ADC5E-9A2A-4DA5-8CBA-71FBB5B74AEF

Q28305293-4E35A4B5-486A-4531-8CF3-C295B97F5595

Q28305293-54853775-5EE6-4078-A37D-22BF008589B1

Q28305293-5BC75035-D906-48DA-9607-11D57F7F53A3

Q28305293-773BFA8B-6AA2-434B-ADA5-6C7DD135A1FF

Q28305293-7BF5CD54-CF12-4B6F-932E-7D4468CE8D3C

Q28305293-AD5CB09C-A75B-4136-AB28-FB20A27B9A89

Q28305293-C1142396-1DBA-456C-B101-376227C3C5B8

P304

Q28305293-52357DD9-F557-4429-A145-C446EB0935EA

P31

Q28305293-C63E0C8F-5DF9-4E24-962A-71136F06C9BC

P3181

Q28305293-E3623FE3-D4A8-4321-957B-F47A4B4FC768

P356

Q28305293-CCF17DB8-7DC3-46CD-A501-0D5C37BBFE3E

P407

Q28305293-E2AA7E4A-B799-44E5-9E7F-3E459E6FB0E5

P433

Q28305293-2C4CA34B-59AC-4214-A220-473D042350EB

P478

Q28305293-7F9E475B-9CE8-401E-A490-09036A250317

P50

Q28305293-67A44E2A-D10E-4F74-BFC1-DBDE769B1B68

Q28305293-DA318A13-C61A-4C90-88EF-469D86DB55E9

P577

Q28305293-F8BE65CA-31F3-4B91-9A50-C61CF669C662

P698

Q28305293-0C2CE88B-B655-4DDC-88AC-357B0E1DD2E6

P921

Q28305293-88B3A4A1-B832-460E-B21A-045A5CB17233

Q28305293-A5A1C434-9920-440D-AD9B-707BB9D526D2

P3181

P356

JCO.2008.20.8397

P1433

Journal of Clinical Oncology

P1476

Fluorouracil, leucovorin, and ...... f metastatic colorectal cancer

@en

P2093

Anatoly Makhson

http://www.w3.org/2001/XMLSchema#string

Angela Zubel

http://www.w3.org/2001/XMLSchema#string

Anja H Loos

http://www.w3.org/2001/XMLSchema#string

Carsten Bokemeyer

http://www.w3.org/2001/XMLSchema#string

Christopher Stroh

http://www.w3.org/2001/XMLSchema#string

Gunter Schuch

http://www.w3.org/2001/XMLSchema#string

Heinz Ludwig

http://www.w3.org/2001/XMLSchema#string

Joerg T Hartmann

http://www.w3.org/2001/XMLSchema#string

Jorge Aparicio

http://www.w3.org/2001/XMLSchema#string

Piotr Koralewski

http://www.w3.org/2001/XMLSchema#string

P304

663-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

191237

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2008.20.8397

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Filippo de Braud

Igor N. Bondarenko

P577

2008-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19114683

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer